Swiss National Bank Provention Bio, Inc. Transaction History

Swiss National Bank

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 10, 2023	SELL	$6.7 - $24.21 $55,610 - $200,943	-8,300 Reduced 4.44%	178,800 $4.31 Million
Q4 2022 Feb 08, 2023	BUY	$4.52 - $10.57 $272,104 - $636,314	60,200 Added 47.44%	187,100 $1.98 Million
Q2 2022 Aug 09, 2022	BUY	$3.65 - $7.3 $52,925 - $105,850	14,500 Added 12.9%	126,900 $508,000
Q1 2022 May 09, 2022	BUY	$3.4 - $7.88 $25,840 - $59,888	7,600 Added 7.25%	112,400 $823,000
Q2 2021 Aug 06, 2021	SELL	$6.71 - $11.04 $18,117 - $29,807	-2,700 Reduced 2.51%	104,800 $883,000
Q1 2021 May 07, 2021	BUY	$10.12 - $19.45 $186,208 - $357,880	18,400 Added 20.65%	107,500 $1.13 Million
Q4 2020 Feb 05, 2021	BUY	$11.79 - $18.94 $35,370 - $56,820	3,000 Added 3.48%	89,100 $1.51 Million
Q2 2020 Aug 05, 2020	BUY	$7.81 - $17.0 $672,441 - $1.46 Million	86,100 New	86,100 $1.22 Million

170K

Ticker PRVB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 81,549,904
Description
Provention Bio, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics and solutions to intercept and prevent immune-mediated diseases. Its products candidates include PRV-031 teplizumab and monoclonal antibodies (mAb) that is in Phase III clinical trial for the interception of type one...

Get notified when there are updates to the investment portfolio of Swiss National Bank, based on Form 13F filings with the SEC.

Stay updated on Swiss National Bank with notifications on news.